Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Iman Touati, Mohnad Abdalla, Naif H. Ali, Raed AlRuwaili, Mubarak Alruwaili, Mohammed Reda Britel & Amal Maurady. (2023) Constituents of Stachys plants as potential dual inhibitors of AChE and NMDAR for the treatment of Alzheimer’s disease: a molecular docking and dynamic simulation study. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-17.
Read now
Read now
Olubukola Benedicta Ojo, Abigail Oladunni Olajide, Grace Boluwatife Olagunju, Comfort Olowu, Sunday Solomon Josiah, Zainab Abiola Amoo, Mary Tolulope Olaleye & Afolabi Clement Akinmoladun. (2023) Polyphenol-rich Spondias mombin leaf extract abates cerebral ischemia/reperfusion-induced disturbed glutamate-ammonia metabolism and multiorgan toxicity in rats. Biomarkers 28:1, pages 65-75.
Read now
Read now
Khalid A. Agha, Nader E. Abo-Dya, Abdul Rashid Issahaku, Clement Agoni, Mahmoud E. S. Soliman, Eatedal H. Abdel-Aal, Zakaria K. Abdel-Samii & Tarek S. Ibrahim. (2022) Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist: simulation-guided analogue design and pharmacological screening. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 1241-1256.
Read now
Read now
Tomoyuki Nagata, Shunichiro Shinagawa, Shinichiro Nakajima, Yoshihiro Noda & Masaru Mimura. (2022) Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. Expert Opinion on Pharmacotherapy 23:6, pages 727-737.
Read now
Read now
Articles from other publishers (29)
Bhawana Sati, Tyagi Alka & Anurag Chaudhary. (2023) Structural Scaffolds as Anti- Alzheimer Agents. Medicinal Chemistry 19:2, pages 132-146.
Crossref
Crossref
Azadeh Eskandary & Ahmad Ali Moazedi. (2022) The Effect of Lovastatin on the Electrophysiological Properties of CA1 Pyramidal Neurons in a Rat Model of Alzheimer Disease. Zahedan Journal of Research in Medical Sciences 24:3.
Crossref
Crossref
Märta Dahlström, Nather Madjid, Gunnar Nordvall, Magnus M. Halldin, Erika Vazquez-Juarez, Maria Lindskog, Johan Sandin, Bengt Winblad, Maria Eriksdotter & Pontus Forsell. (2021) Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. Cells 10:8, pages 1871.
Crossref
Crossref
Mark J. Millan, Anne Dekeyne, Alain Gobert, Mauricette Brocco, Clotilde Mannoury la Cour, Jean-Claude Ortuno, David Watson & Kevin C.F. Fone. (2020) Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology 177, pages 108099.
Crossref
Crossref
Samuele Maramai, Mohamed Benchekroun, Moustafa T. Gabr & Samir Yahiaoui. (2020) Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations. BioMed Research International 2020, pages 1-27.
Crossref
Crossref
F. Javier Pérez-Areales, Andreea L. Turcu, Marta Barniol-Xicota, Caterina Pont, Deborah Pivetta, Alba Espargaró, Manuela Bartolini, Angela De Simone, Vincenza Andrisano, Belén Pérez, Raimon Sabate, Francesc X. Sureda, Santiago Vázquez & Diego Muñoz-Torrero. (2019) A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. European Journal of Medicinal Chemistry 180, pages 613-626.
Crossref
Crossref
George T. Grossberg, Gary Tong, Anna D. Burke & Pierre N. Tariot. (2019) Present Algorithms and Future Treatments for Alzheimer’s Disease. Journal of Alzheimer's Disease 67:4, pages 1157-1171.
Crossref
Crossref
Zohreh Zare, Mohsen Tehrani, Noorollah Rezaei, Babak Dana Ghalebarzand & Moslem Mohammadi. (2019) Anxiolytic activity of paraoxon is associated with alterations in rat brain glutamatergic system. Neurotoxicology and Teratology 71, pages 32-40.
Crossref
Crossref
Kenji Ishibashi, Keita Sakurai, Keigo Shimoji, Aya M. Tokumaru & Kenji Ishii. (2018) Altered functional connectivity of the default mode network by glucose loading in young, healthy participants. BMC Neuroscience 19:1.
Crossref
Crossref
Kazuki Ide, Norihiro Matsuoka, Hiroshi Yamada, Daisuke Furushima & Koji Kawakami. (2018) Effects of Tea Catechins on Alzheimer’s Disease: Recent Updates and Perspectives. Molecules 23:9, pages 2357.
Crossref
Crossref
Brahim Gargouri, Harsharan S. Bhatia, Michèle Bouchard, Bernd L. Fiebich & Hamadi Fetoui. (2018) Inflammatory and oxidative mechanisms potentiate bifenthrin-induced neurological alterations and anxiety-like behavior in adult rats. Toxicology Letters 294, pages 73-86.
Crossref
Crossref
Cosimo Walter D'Acunto, Robert Kaplánek, Helena Gbelcová, Zdeněk Kejík, Tomáš Bříza, Liudmila Vasina, Martin Havlík, Tomáš Ruml & Vladimír Král. (2018) Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties. European Journal of Medicinal Chemistry 150, pages 140-155.
Crossref
Crossref
Fred G. Oliveira-Souza, Marci L. DeRamus, Thomas van Groen, Alexis E. Lambert, Mark S. Bolding & Christianne E. Strang. (2017) Retinal changes in the Tg-SwDI mouse model of Alzheimer’s disease. Neuroscience 354, pages 43-53.
Crossref
Crossref
Qi Li, Hongyu Yang, Yao Chen & Haopeng Sun. (2017) Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. European Journal of Medicinal Chemistry 132, pages 294-309.
Crossref
Crossref
Zahra Mokhtari, Tourandokht Baluchnejadmojarad, Farnaz Nikbakht, Monireh Mansouri & Mehrdad Roghani. (2017) Riluzole ameliorates learning and memory deficits in Aβ25-35-induced rat model of Alzheimer’s disease and is independent of cholinoceptor activation. Biomedicine & Pharmacotherapy 87, pages 135-144.
Crossref
Crossref
Zdeněk Fišar. (2016) Drugs related to monoamine oxidase activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 69, pages 112-124.
Crossref
Crossref
Chennakesavan Karthick, Sabapathy Periyasamy, Kesavan S. Jayachandran & Muthuswamy Anusuyadevi. (2016) Intrahippocampal Administration of Ibotenic Acid Induced Cholinergic Dysfunction via NR2A/NR2B Expression: Implications of Resveratrol against Alzheimer Disease Pathophysiology. Frontiers in Molecular Neuroscience 9.
Crossref
Crossref
M. Yu. Stepanichev, D. A. Markov, S. V. Freiman, O. A. Frolova, S. N. Omelyanchik, T. A. Borodina, M. R. Novikova, N. P. Kanunnikova, M. V. Onufriev, A. G. Moiseenok & N. V. Gulyaeva. (2016) Combined treatment with pantothenic acid derivatives and memantine alleviates scopolamine-induced amnesia in rats: The involvement of the thiol redox state and coenzyme A. Neurochemical Journal 10:2, pages 120-130.
Crossref
Crossref
Carlos H. Rojas-Fernandez. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
29
48
.
Radoslaw Magierski & Tomasz Sobow. (2015) Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegenerative Disease Management 5:5, pages 445-462.
Crossref
Crossref
Fani Koukouli & Uwe Maskos. (2015) The multiple roles of the α7 nicotinic acetylcholine receptor in modulating glutamatergic systems in the normal and diseased nervous system. Biochemical Pharmacology 97:4, pages 378-387.
Crossref
Crossref
Galina F. Makhaeva, Sofya V. Lushchekina, Natalia P. Boltneva, Vladimir B. Sokolov, Vladimir V. Grigoriev, Olga G. Serebryakova, Ekaterina A. Vikhareva, Alexey Yu. Aksinenko, George E. Barreto, Gjumrakch Aliev & Sergey O. Bachurin. (2015) Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. Scientific Reports 5:1.
Crossref
Crossref
Megan J. Ehret & Kevin W. Chamberlin. (2015) Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?. Clinical Therapeutics 37:8, pages 1604-1616.
Crossref
Crossref
Ivor S. Ebenezer. 2015. Neuropsychopharmacology and Therapeutics. Neuropsychopharmacology and Therapeutics
310
326
.
Syed Nuruddin, Gry Helen Enger Syverstad, Sveinung Lillehaug, Trygve B. Leergaard, Lars N. G. Nilsson, Erik Ropstad, Anette Krogenæs, Ira Ronit Hebold Haraldsen & Reidun Torp. (2014) Elevated mRNA-Levels of Gonadotropin-Releasing Hormone and Its Receptor in Plaque-Bearing Alzheimer's Disease Transgenic Mice. PLoS ONE 9:8, pages e103607.
Crossref
Crossref
Claire J. Williams & David T. Dexter. (2014) Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease. Journal of Neurochemistry 129:1, pages 4-20.
Crossref
Crossref
M Zimmermann. (2013) Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?. British Journal of Pharmacology 170:5, pages 953-967.
Crossref
Crossref
. 2013. How to Manage Dementia in General Practice. How to Manage Dementia in General Practice
41
52
.
Anne CorbettPaul FrancisClive Ballard. (2013) Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. Clinical Medicine Insights: Therapeutics 5, pages CMT.S7794.
Crossref
Crossref